急性期医療シンドロミック検査の世界市場レポート 2025年

急性期医療シンドロミック検査市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR12.9％で75億米ドルに成長します。予測期間中の成長は、感染症の流行増加、より迅速な診断ソリューションへの需要増加、ヘルスケアサービスの拡大、マルチプレックス・シンドロミック・パネルの利用拡大、高齢者人口の増加などに起因すると考えられます。この期間に予想される主な発展動向には、ポイントオブケア検査へのシフト、クラウドベースのプラットフォームの統合、マルチプレックスパネルの採用、AI搭載ツールの開発、シンドロミック検査における自動化の進展などがあります。

感染症の流行の増加は、急性期医療シンドロミック検査市場の成長を促進すると予想されます。感染症は、細菌、ウイルス、真菌、寄生虫などの有害な微生物によって引き起こされ、人との接触、動物、環境を通じて広がる可能性があります。人口増加、都市化、世界の旅行、抗菌剤耐性、気候変動などの治療要因がこれらの疾患の発生率上昇に寄与しており、効果的な診断・治療ソリューションに対する需要が高まっています。急性期医療シンドロミック検査は、マルチプレックス分子診断によって病原体や重複感染を特定し、的を絞った治療を決定する上で重要な役割を果たしています。例えば、2024年2月、英国健康安全保障局は、2024年第4週のインフルエンザ陽性率が前週の14.0%から16.6%に上昇したと報告しました。インフルエンザ様疾患（ILI）の受診率も上昇し、10万人あたり9.8人（前週は7.5人）に達し、インフルエンザによる入院患者数は10万人あたり5.12人から7.63人に増加しました。その結果、感染症罹患率の増加が急性期医療シンドロミック検査市場の拡大に拍車をかけています。

急性期医療シンドロミック検査市場の主要企業は、マルチプレックス・リアルタイム・ポリメラーゼ連鎖反応（PCR）技術の進歩を活用し、診断精度の向上、迅速な病原体の検出、検査室のワークフローの合理化、ターンアラウンドタイムの短縮を実現しています。マルチプレックス・リアルタイムPCRは、1回の反応で複数の病原体や遺伝子標的を同時に検出・定量する高度な分子診断法であり、疾病診断の効率と精度を向上させる。2023年4月、オランダのバイオテクノロジー企業であるQIAGEN N.V.は、日本でQIAstat-Dxシンドロミック検査ソリューションを発売しました。このシステムの特徴は、1検体から20以上の病原体を検出できるSARS-CoV-2呼吸器パネルです。マルチプレックス・リアルタイムPCR技術を使用し、従来のPCRアッセイと比較して最小限の労力で迅速な結果が得られます。2022年末までに、世界中で3,500台以上のQIAstat-Dxシステムが導入され、呼吸器、消化器、髄膜炎関連疾患の診断に役立っています。100カ国以上で利用可能なこのシステムは、シンドロミック検査への世界のアクセスを向上させています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界急性期医療シンドロミック検査PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の急性期医療シンドロミック検査市場：成長率分析
• 世界の急性期医療シンドロミック検査市場の実績：規模と成長, 2019-2024
• 世界の急性期医療シンドロミック検査市場の予測：規模と成長, 2024-2029, 2034F
• 世界急性期医療シンドロミック検査総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の急性期医療シンドロミック検査市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 呼吸器疾患
• 消化器疾患
• 泌尿器疾患
• 熱帯病
• その他の病気の種類
• 世界の急性期医療シンドロミック検査市場サンプルタイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血
• 尿
• 生体液
• スツール
• 綿棒
• その他のサンプルタイプ
• 世界の急性期医療シンドロミック検査市場ターゲット別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 細菌
• ウイルス
• 菌類
• 寄生虫
• 世界の急性期医療シンドロミック検査市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 臨床および診断検査室
• 調査・学術機関
• その他のエンドユーザー
• 世界の急性期医療シンドロミック検査市場呼吸器疾患の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• インフルエンザ
• 呼吸器合胞体ウイルス（RSV）
• COVID-19
• 結核
• その他の呼吸器疾患
• 世界の急性期医療シンドロミック検査市場消化器疾患の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• クロストリジウム・ディフィシル感染症
• ノロウイルス
• ロタウイルス
• サルモネラ
• その他の消化器疾患
• 世界の急性期医療シンドロミック検査市場泌尿器疾患の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 尿路感染症（UTI）
• 性感染症（STI）
• 膣感染症
• その他の泌尿生殖器疾患
• 世界の急性期医療シンドロミック検査市場熱帯病の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• マラリア
• デング熱
• チクングニア熱
• ジカウイルス
• その他の熱帯病
• 世界の急性期医療シンドロミック検査市場、その他の疾患タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 髄膜炎
• 敗血症
• その他の新興感染症

第7章 地域別・国別分析

• 世界の急性期医療シンドロミック検査市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の急性期医療シンドロミック検査市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 急性期医療シンドロミック検査市場：競合情勢
• 急性期医療シンドロミック検査市場：企業プロファイル
  • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
  • Becton, Dickinson and Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Seegene Inc.
• bioMerieux SA
• Sysmex Corporation
• Bio-Rad Laboratories Inc.
• QIAGEN N.V.
• Werfen
• DiaSorin S.p.A.
• Quidel Corporation
• Luminex Corporation
• Biocartis NV
• Microbiologics Inc.
• QuantuMDx Group Ltd.
• Curetis GmbH by OpGen Inc.
• Genetic Signatures Ltd.
• Applied BioCode Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 急性期医療シンドロミック検査市場2029：新たな機会を提供する国
• 急性期医療シンドロミック検査市場2029：新たな機会を提供するセグメント
• 急性期医療シンドロミック検査市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Acute care syndromic testing is a rapid molecular diagnostic approach that detects multiple pathogens simultaneously from a single patient sample. Primarily used in emergency and critical care settings, it enables quicker diagnosis of infectious diseases, leading to faster treatment decisions, improved patient outcomes, and reduced hospital stays.

The main disease types in the acute care syndromic testing market include respiratory diseases, gastrointestinal diseases, genitourinary diseases, tropical diseases, and others. Respiratory diseases affect the lungs, airways, and respiratory tract, causing symptoms such as coughing, shortness of breath, and fever. Various sample types used for testing include blood, urine, biofluids, stool, swabs, and more. The tests target bacteria, viruses, fungi, and parasites and are utilized in hospitals, clinical and diagnostic laboratories, research and academic institutions, and other healthcare settings.

The acute care syndromic testing market research report is one of a series of new reports from The Business Research Company that provides acute care syndromic testing market statistics, including the acute care syndromic testing industry's global market size, regional shares, competitors with a acute care syndromic testing market share, detailed acute care syndromic testing market segments, market trends and opportunities, and any further data you may need to thrive in the acute care syndromic testing industry. This acute care syndromic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The acute care syndromic testing market size has grown rapidly in recent years. It will grow from $4.08 billion in 2024 to $4.62 billion in 2025 at a compound annual growth rate (CAGR) of 13.2%. The growth during the historic period can be attributed to increasing awareness of antimicrobial resistance, rising government funding for infectious disease research, greater investment in healthcare infrastructure, a growing focus on syndromic testing, the expansion of telemedicine, and the rising prevalence of infectious diseases.

The acute care syndromic testing market size is expected to see rapid growth in the next few years. It will grow to $7.50 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The growth during the forecast period can be attributed to the rising prevalence of infectious diseases, increasing demand for faster diagnostic solutions, the expansion of healthcare services, the growing use of multiplex syndromic panels, and a rising geriatric population. Key trends expected during this period include a shift toward point-of-care testing, the integration of cloud-based platforms, the adoption of multiplex panels, the development of AI-powered tools, and increased automation in syndromic testing.

The increasing prevalence of infectious diseases is expected to drive the growth of the acute care syndromic testing market. Infectious diseases, caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, can spread through human contact, animals, or the environment. Factors such as population growth, urbanization, global travel, antimicrobial resistance, and climate change are contributing to the rising incidence of these diseases, increasing the demand for effective diagnostic and treatment solutions. Acute care syndromic testing plays a crucial role in identifying pathogens and co-infections through multiplex molecular diagnostics, allowing for targeted treatment decisions. For example, in February 2024, the UK Health Security Agency reported that in week 4 of 2024, the influenza positivity rate rose to 16.6%, up from 14.0% the previous week. Influenza-like illness (ILI) consultations also increased, reaching 9.8 per 100,000 people compared to 7.5 per 100,000 in the prior week, while influenza hospitalizations climbed from 5.12 to 7.63 per 100,000. Consequently, the growing incidence of infectious diseases is fueling the expansion of the acute care syndromic testing market.

Leading companies in the acute care syndromic testing market are leveraging advancements in multiplex real-time polymerase chain reaction (PCR) technology to enhance diagnostic accuracy, enable rapid pathogen detection, streamline laboratory workflows, and reduce turnaround time. Multiplex real-time PCR is an advanced molecular diagnostic method that simultaneously detects and quantifies multiple pathogens or genetic targets in a single reaction, improving efficiency and accuracy in disease diagnosis. In April 2023, QIAGEN N.V., a Netherlands-based biotechnology company, launched the QIAstat-Dx syndromic testing solution in Japan. This system features a SARS-CoV-2 respiratory panel capable of detecting over 20 pathogens from a single sample. Using multiplex real-time PCR technology, it provides rapid results with minimal labor compared to traditional PCR assays. By the end of 2022, over 3,500 QIAstat-Dx systems had been installed worldwide, aiding in the diagnosis of respiratory, gastrointestinal, and meningitis-related conditions. Available in more than 100 countries, this system is improving global access to syndromic testing.

In May 2023, Applied BioCode, a US-based biotechnology company, partnered with Medline Industries to expand the distribution of the BioCode MDx-3000 System. This collaboration aims to enhance access to diagnostic testing for hospitals and reference laboratories across the U.S. Medline Industries LP, a US-based healthcare company specializing in medical supplies and healthcare services, will support the distribution of Applied BioCode's multiplex diagnostic solutions, further advancing syndromic testing capabilities.

Major players in the acute care syndromic testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company, Seegene Inc., bioMerieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Werfen, DiaSorin S.p.A., Quidel Corporation, Luminex Corporation, Biocartis NV, Microbiologics Inc., QuantuMDx Group Ltd., Curetis GmbH by OpGen Inc., Genetic Signatures Ltd., and Applied BioCode Inc.

North America was the largest region in the acute care syndromic testing market in 2024. The regions covered in acute care syndromic testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acute care syndromic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acute care syndromic testing market consists of revenues earned by entities by providing services such as comprehensive pathogen detection, rapid turnaround time, and support for antimicrobial stewardship. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute care syndromic testing market also includes sales of blood collection tubes, or urine containers, PCR and RT-PCR machines, and reader devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acute Care Syndromic Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute care syndromic testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acute care syndromic testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute care syndromic testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Respiratory Diseases; Gastrointestinal Diseases; Genitourinary Diseases; Tropical Diseases; Other Disease Types
• 2) By Sample Type: Blood; Urine; Biofluids; Stool; Swabs; Other Sample Types
• 3) By Target: Bacteria; Viruses; Fungi; Parasites
• 4) By End User: Hospitals; Clinical And Diagnostic Laboratories; Research And Academic Institutions; Other End Users
• Subsegments:
• 1) By Respiratory Diseases: Influenza; Respiratory Syncytial Virus (RSV); COVID-19; Tuberculosis; Other Respiratory Diseases
• 2) By Gastrointestinal Diseases: Clostridium Difficile Infection; Norovirus; Rotavirus; Salmonella; Other Gastrointestinal Diseases
• 3) By Genitourinary Diseases: Urinary Tract Infections (UTIs); Sexually Transmitted Infections (STIs); Vaginal Infections; Other Genitourinary Diseases
• 4) By Tropical Diseases: Malaria; Dengue; Chikungunya; Zika Virus; Other Tropical Diseases
• 5) By Other Disease Types: Meningitis; Sepsis; Other Emerging Infectious Diseases
• Companies Mentioned: Siemens Healthineers AG; F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; Danaher Corporation; Becton, Dickinson and Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Acute Care Syndromic Testing Market Characteristics

3. Acute Care Syndromic Testing Market Trends And Strategies

4. Acute Care Syndromic Testing Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Acute Care Syndromic Testing Growth Analysis And Strategic Analysis Framework

• 5.1. Global Acute Care Syndromic Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Acute Care Syndromic Testing Market Growth Rate Analysis
• 5.4. Global Acute Care Syndromic Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Acute Care Syndromic Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Acute Care Syndromic Testing Total Addressable Market (TAM)

6. Acute Care Syndromic Testing Market Segmentation

• 6.1. Global Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Respiratory Diseases
• Gastrointestinal Diseases
• Genitourinary Diseases
• Tropical Diseases
• Other Disease Types
• 6.2. Global Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood
• Urine
• Biofluids
• Stool
• Swabs
• Other Sample Type
• 6.3. Global Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bacteria
• Viruses
• Fungi
• Parasites
• 6.4. Global Acute Care Syndromic Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinical And Diagnostic Laboratories
• Research And Academic Institutions
• Other End Users
• 6.5. Global Acute Care Syndromic Testing Market, Sub-Segmentation Of Respiratory Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Influenza
• Respiratory Syncytial Virus (RSV)
• COVID-19
• Tuberculosis
• Other Respiratory Diseases
• 6.6. Global Acute Care Syndromic Testing Market, Sub-Segmentation Of Gastrointestinal Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clostridium Difficile Infection
• Norovirus
• Rotavirus
• Salmonella
• Other Gastrointestinal Diseases
• 6.7. Global Acute Care Syndromic Testing Market, Sub-Segmentation Of Genitourinary Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Urinary Tract Infections (UTIs)
• Sexually Transmitted Infections (STIs)
• Vaginal Infections
• Other Genitourinary Diseases
• 6.8. Global Acute Care Syndromic Testing Market, Sub-Segmentation Of Tropical Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Malaria
• Dengue
• Chikungunya
• Zika Virus
• Other Tropical Diseases
• 6.9. Global Acute Care Syndromic Testing Market, Sub-Segmentation Of Other Disease Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Meningitis
• Sepsis
• Other Emerging Infectious Diseases

7. Acute Care Syndromic Testing Market Regional And Country Analysis

• 7.1. Global Acute Care Syndromic Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Acute Care Syndromic Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acute Care Syndromic Testing Market

• 8.1. Asia-Pacific Acute Care Syndromic Testing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acute Care Syndromic Testing Market

• 9.1. China Acute Care Syndromic Testing Market Overview
• 9.2. China Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acute Care Syndromic Testing Market

• 10.1. India Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acute Care Syndromic Testing Market

• 11.1. Japan Acute Care Syndromic Testing Market Overview
• 11.2. Japan Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acute Care Syndromic Testing Market

• 12.1. Australia Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acute Care Syndromic Testing Market

• 13.1. Indonesia Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acute Care Syndromic Testing Market

• 14.1. South Korea Acute Care Syndromic Testing Market Overview
• 14.2. South Korea Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acute Care Syndromic Testing Market

• 15.1. Western Europe Acute Care Syndromic Testing Market Overview
• 15.2. Western Europe Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acute Care Syndromic Testing Market

• 16.1. UK Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acute Care Syndromic Testing Market

• 17.1. Germany Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acute Care Syndromic Testing Market

• 18.1. France Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acute Care Syndromic Testing Market

• 19.1. Italy Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acute Care Syndromic Testing Market

• 20.1. Spain Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acute Care Syndromic Testing Market

• 21.1. Eastern Europe Acute Care Syndromic Testing Market Overview
• 21.2. Eastern Europe Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acute Care Syndromic Testing Market

• 22.1. Russia Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acute Care Syndromic Testing Market

• 23.1. North America Acute Care Syndromic Testing Market Overview
• 23.2. North America Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acute Care Syndromic Testing Market

• 24.1. USA Acute Care Syndromic Testing Market Overview
• 24.2. USA Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acute Care Syndromic Testing Market

• 25.1. Canada Acute Care Syndromic Testing Market Overview
• 25.2. Canada Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acute Care Syndromic Testing Market

• 26.1. South America Acute Care Syndromic Testing Market Overview
• 26.2. South America Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acute Care Syndromic Testing Market

• 27.1. Brazil Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acute Care Syndromic Testing Market

• 28.1. Middle East Acute Care Syndromic Testing Market Overview
• 28.2. Middle East Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acute Care Syndromic Testing Market

• 29.1. Africa Acute Care Syndromic Testing Market Overview
• 29.2. Africa Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acute Care Syndromic Testing Market Competitive Landscape And Company Profiles

• 30.1. Acute Care Syndromic Testing Market Competitive Landscape
• 30.2. Acute Care Syndromic Testing Market Company Profiles
  • 30.2.1. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Becton, Dickinson and Company Overview, Products and Services, Strategy and Financial Analysis

31. Acute Care Syndromic Testing Market Other Major And Innovative Companies

• 31.1. Seegene Inc.
• 31.2. bioMerieux SA
• 31.3. Sysmex Corporation
• 31.4. Bio-Rad Laboratories Inc.
• 31.5. QIAGEN N.V.
• 31.6. Werfen
• 31.7. DiaSorin S.p.A.
• 31.8. Quidel Corporation
• 31.9. Luminex Corporation
• 31.10. Biocartis NV
• 31.11. Microbiologics Inc.
• 31.12. QuantuMDx Group Ltd.
• 31.13. Curetis GmbH by OpGen Inc.
• 31.14. Genetic Signatures Ltd.
• 31.15. Applied BioCode Inc.

32. Global Acute Care Syndromic Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acute Care Syndromic Testing Market

34. Recent Developments In The Acute Care Syndromic Testing Market

35. Acute Care Syndromic Testing Market High Potential Countries, Segments and Strategies

• 35.1 Acute Care Syndromic Testing Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Acute Care Syndromic Testing Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Acute Care Syndromic Testing Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer